Sandoz, manufacturer of generic and biosimilar medicines, makes an investment of approximately EUR 25 million in its site in Holzkirchen, Germany, to expand its Biopharma Technical Development (BioTD) capabilities and complete a state-of-the-art biotech lab by Q4 2023. The Center for Analytical Characterization is expected to support the future growth of biosimilars.
As a result of the investment, Holzkirchen will become one of the primary technical locations for biosimilar development at Sandoz, bringing together state-of-the-art laboratories and analytical expertise at one site. Combined with a major expansion in 2017, this represents a total investment of nearly EUR 100 million in the company’s German headquarters.
Thomas Weigold, Sandoz Country President, Germany, and CEO of Hexal AG: “Our continued investment in Holzkirchen reflects our commitment to expanding our BioTD capabilities and reinforces our dedication to providing high-quality biosimilars to patients worldwide.”
Sandoz has also submitted a request to the Bavarian State Government for research funding to strengthen its development capabilities.
Prime Minister Dr. Markus Söder: “The Free State of Bavaria strongly supports the continued expansion of Sandoz in Holzkirchen. This investment not only strengthens Bavaria’s position as a leading biotechnology hub but also creates new opportunities for research and development, spurring innovation and job growth.”
Dr. Florian Bieber, Development Platform Head, Biopharmaceuticals, and Chief Medical Officer, Sandoz: “With its central European location and close proximity to Munich, Holzkirchen is ideally situated to attract the top talent needed to establish the site as of a growing network of BioTD centers. In addition, we are increasing our efforts to explore areas of mutual interest and collaboration in bio development with the renowned local universities and research institutes.”
Up to 45 full-time employees are to be hired for the capacity expansion.